Flunixin
Title: Flunixin
CAS Registry Number: 38677-85-9
CAS Name: 2-[[2-Methyl-3-(trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic acid
Additional Names: 2-(2-methyl-3-trifluoromethylanilino)nicotinic acid; 2-(a3,a3,a3-trifluoro-2,3-xylidino)nicotinic acid
Manufacturers' Codes: Sch-14714
Molecular Formula: C14H11F3N2O2
Molecular Weight: 296.24
Percent Composition: C 56.76%, H 3.74%, F 19.24%, N 9.46%, O 10.80%
Literature References: Cyclooxygenase inhibitor. Prepn: M. H. Sherlock, N. Sperber, BE 679271; eidem, US 3337570 (1966, 1967 both to Schering). Prepn of the acid and meglumine salt: M. H. Sherlock, BE 812772; idem, US 3839344 (both 1974 to Schering). Pharmacodynamics in horses: M. M. Hardee, J. N. Moore, Res. Vet. Sci. 40, 152 (1986); and pharmacokinetics: L. R. Soma et al., J. Vet. Pharmacol. Ther. 15, 292 (1992). GC determn in urine: M. Johansson, E. -L. Anlér, J. Chromatogr. 427, 55 (1988). Clinical evaluation in horses: J. W. Houdeshell, P. W. Hennessey, J. Equine Med. Surg. 1, 57 (1977). Experimental use in food-producing animals: M. Kopcha, A. S. Ahl, J. Am. Vet. Med. Assoc. 194, 45 (1989). Comparative toxicological study in horses: C. G. MacAllister et al., ibid. 202, 71 (1993).
Properties: Crystals from acetone/hexane, mp 226-228°. pKa¢ 5.82.
Melting point: mp 226-228°
pKa: pKa¢ 5.82
 
Derivative Type: Meglumine salt
CAS Registry Number: 42461-84-7
Trademarks: Banamine (Schering-Plough); Binixin (Bayer); Finadyne (Fisons)
Molecular Formula: C14H11F3N2O2.C7H17NO5
Molecular Weight: 491.46
Percent Composition: C 51.32%, H 5.74%, F 11.60%, N 8.55%, O 22.79%
Properties: Colorless cryst from ethanol/ether, mp 135-137°. Crystals from acetonitrile, mp 136-139°. Sol in water.
Melting point: mp 135-137°; mp 136-139°
 
Therap-Cat-Vet: Anti-inflammatory; analgesic; antipyretic.

Others monographs:
PhosphorusN-Methylephedrine4-MethylaminorexCyclic GMP
AnilazineChromic AcetatePhosphocysteamineSilver Oxalate
Stannous PyrophosphateCarboxinPolybenzarsolFlocoumafen
AlbomycinGitoxin2,2,3,3,4,4,5,5-Octafluoro-1-pentanolIsoeugenol
©2016 DrugLead US FDA&EMEA